Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +16.10%
#2 Fake World Assets Fake World Assets +11.89%
#3 OriginTrail OriginTrail +8.84%
#4 B3 (Base) B3 (Base) +7.77%
#5 Pons Pons +5.38%
#6 Storj Storj +5.13%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +4.30%
#8 Audiera Audiera +3.81%
#9 Strategy PP Variable xStock Strategy PP Variable xStock +3.03%
#10 Geodnet Geodnet +2.92%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Setări
Limbă
ROMâNă
Monedă
USD
Temă
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
Rang în acțiuni #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
Preț acțiune
$1.54
Ultima sincronizare: 2024-04-08
Capitalizare de piață
$119.21M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează NGM Biopharmaceuticals, Inc. (NGM)

Categorie

Healthcare
Câștiguri pentru NGM Biopharmaceuticals, Inc. (NGM)
Câștiguri în 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale NGM Biopharmaceuticals, Inc., câștigurile actuale ale companiei sunt 0. În anul 2026, compania a înregistrat un câștig de 0, egal cu câștigului din 2026, care a fost de 0. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru NGM Biopharmaceuticals, Inc. din 2026 până în 2026
Câștiguri la sfârșitul fiecărui an
An Câștiguri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Câștiguri pentru companii similare sau concurente
Companie Câștiguri Diferență de câștiguri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH